Alisertib Early Access Program

Puma Biotechnology Inc. is a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer.`

Alisertib, also known as MLN8237 is a selective small molecule inhibitor of Aurora A kinase that is being developed for the treatment of advanced malignancies. Alisertib may have potential applications across a broad range of human tumors, given the essential role of mitosis in tumor proliferation.

Caligor Coghlan (CalCog) is a specialty global pharmaceutical and services business dedicated to serving patients, the community and the healthcare industry. CalCog has compiled a team of experts in implementing global named patient programs. CalCog will manage the Alisertib Early Access Program on behalf of Puma Biotechnology Inc..